The 3DTwin Screen is designed to support classical chemotherapies, targeted therapies, and immune-oncological drugs, whether used as mono-therapy or in combination.
3D tumor twin model
Recent results from a proof-of-concept study with Non-Small Cell Lung Cancer (NSCLC) demonstrated remarkable success in achieving immune checkpoint inhibitor-mediated tumor remission.
Combinatorial drug testing
Combining different types of drugs has been proven to be one of the most effective ways to fight cancer. However, evaluating the effectiveness of drug combinations can be a tedious and time-consuming process. PreComb’s cutting-edge 3DTwin® Technology allows to directly evaluate whether two or more drugs have an added value, saving precious time and effort. With the 3DTwin Screen, researchers and clinicians can easily test and optimize drug combinations for maximum efficacy, leading to better patient outcomes.
With PreComb’s 3DTwin® Technology, researchers and clinicians can now perform unbiased testing to determine the effectiveness of targeted therapies, even in cases where targets cannot be identified or therapies have proven ineffective. The 3DTwin® Technology is designed to support clinical decision-making by providing a comprehensive screening platform that utilizes advanced technology to analyze a patient’s specific response to a range of drugs. This state-of-the-art screening technology can help drug developers to identify optimal drug combinations and clinicians to identify the best possible treatment options for their patients, reducing the risk of adverse events and improving outcomes.
A promising proof of concept was demonstrated by testing an RAF and an MEK inhibitor in various cancer models that showed distinct clustering behavior.
Despite their severe side effects, chemotherapies are still an important weapon against cancer. With the help of 3DTwin® technology, the different response of single and combinatorial chemotherapies can be shown, as exemplified by tumor twins derived from two patients with non-small cell lung cancer (NSCLC).